Cell Therapy News/Articles, page-14523

Thanks for the share. I don't think a lot of people saw it, hence the lack of commentary. It might have been for a specific bell potter audience. A lot of great points in the video.

It was detailed that last quarter's SUBMISSION was substantial new information to the Investigational New Drug (IND) file - as guided by the FDA. I read that as the "resubmission" people thought they were expecting.

SI reminded us that RemL has Fast Track Designation and BLA Priority Review.

SI goes on to discuss remestemcel-l improving survival in 3 controlled studies:



"the market will be updated in short order regarding long term survival outcomes"... "we expect that we can do better than what it is currently available by a long shot."

A lot to unpack. Not necessarily a whole lot of new information however it certainly helps investors better understand what work has been done, and what is being done.

The comment on GVHD treatment costing up to a million dollars over its lifetime was a bit of an eye-opener. I knew it was significant, but not that significant.

Again, cheers for the share Treed, certainly worth a watch for all investors.